CAR-T therapy shows promise for Hard-to-Treat myeloma
Disease control
Terminated
This study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. The study ai…
Phase: PHASE2 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated May 17, 2026 08:16 UTC